MedTrace Logo

A Study of DEG6498 in Participants With Solid Tumors

NCT07244835 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-13

No results posted yet for this study

Summary

The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors. It will also learn about DEG6498 pharmacokinetics (PK) profile and potential antitumor activity. The main questions it aims to answer are:

* what is an appropriate dose to be given to participants?
* are the side effects of treatment manageable?

Participants who are treated in this study will receive DEG6498 orally once a day and be closely monitored by the treating physicians.

Conditions

  • Malignant Neoplasms

Interventions

DRUG

DEG6498

DEG6498 is an orally bioavailable molecular glue drug that potently induces the degradation of human antigen R (HuR).

Sponsors & Collaborators

  • Degron Therapeutics Co.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-13
Primary Completion
2028-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07244835 on ClinicalTrials.gov